Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma
March 10th 2016Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.
Read More